CoChat

Cationic Antimicrobial Peptides: Issues for Potential Clinical Use

Bradshaw, Jeremy P · 2003 · BioDrugs

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Many different types of organisms use antimicrobial peptides, typically 20-40 amino acids in length, for defence against infection. Most are capable of rapidly killing a wide range of microbial cells. They have been classified according to their active structures into six extensive groups. It is not yet clear how these peptides kill bacterial cells, but it is widely believed that some cationic antimicrobial peptides kill by disrupting bacterial membranes, allowing the free exchange of intra- and extra-cellular ions. The selectivity of these peptides appears to relate to differences between the external membranes of prokaryotic and eukaryotic cells. The action of the peptides may involve the formation of 'barrel-stave' or 'torroidal' pores, the introduction of packing defects in the membrane phospholipids, or large-scale disruption of the membrane by a very dense aggregation of parallel-oriented peptide, called the 'carpet mechanism'. Antimicrobial peptides are attractive candidates for clinical development because of their selectivity, their speed of action and because bacteria may not easily develop resistance against them. Some antimicrobial peptides are already in clinical and commercial use, including ambicin (nisin), polymixin B and gramicidin S. There have been several attempts at developing peptides to make them more suitable for clinical use. For those peptides that act against bacterial membranes, it is possible to differentiate between those structural features that contribute to the specificity of initial membrane binding and those that contribute to the subsequent breach of membrane integrity. The design of novel antimicrobial peptides would necessitate the optimisation of multiple parameters, a problem that has proved difficult to solve. Potential problems to be overcome include high production costs, toxicity against eukaryotic cells, susceptibility to proteolytic degradation and the development of allergies to the peptides. Biosynthesis, using recombinant DNA techniques, could make commercial-scale synthesis feasible but the peptides are usually lethal to the micro-organisms used to produce them. Proteolytic degradation can be reduced by modifying the peptides to contain nonstandard amino acids, or by restricting the use of peptides to topical applications. The problem of sensitisation could be overcome by the use of our own natural antibiotics to prevent or treat infections. Despite early hopes that bacteria would not easily develop resistance to antimicrobial peptides, it is clear that some strains of bacteria already have.

Overview

Integrity signals

Registry

Crossref · 10.2165/00063030-200317040-00002

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 2

  1. Hancock, 2002, FEMS Microbiol Lett, 206, 143, 10.1111/j.1574-6968.2002.tb11000.x · doi:10.1111/j.1574-6968.2002.tb11000.x · Paper page
  2. Gellman, 2001, Biophys J, 80, 2d

Cited by

See all 294

Metadata

Authors
Bradshaw, J. P.
Affiliations
University of Edinburgh (GB)
Corresponding author
Bradshaw, Jeremy P
Venue
BioDrugs
Published
2003
Volume
17
Issue
4
Pages
233-240
ISSN
  • 1172-7039 (ISSN-L)
  • 1173-8804
OpenAlex
W1487871178
Cited by
293
References
27
Citations by year
2026: 6 · 2025: 7 · 2024: 19 · 2023: 18 · 2022: 16 · 2021: 11 · 2020: 25 · 2019: 17 · 2018: 16 · 2017: 17 · 2016: 11 · 2015: 16 · 2014: 13 · 2013: 16 · 2012: 12
FWCI
5.24
Type
journal article
Language
en
Open access
closed
Locations
  • BioDrugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antimicrobial agents and applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
cationic antimicrobial peptides, bacterial membrane disruption, peptide-membrane binding, pore formation, carpet mechanism, peptide selectivity, antimicrobial peptide design, peptide toxicity, proteolysis, antimicrobial resistance, nisin, polymyxin B, gramicidin S
MeSH terms
Animals, Anti-Bacterial Agents, Forecasting, Humans, Structure-Activity Relationship, Technology, Pharmaceutical, Drug Design, Antimicrobial Cationic Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cationic Antimicrobial Peptides: Issues for Potential Clinical Use. https://app.cochat.ai/papers/10.2165/00063030-200317040-00002
The paper
Bradshaw, J. P. (2003). Cationic Antimicrobial Peptides: Issues for Potential Clinical Use. BioDrugs. https://doi.org/10.2165/00063030-200317040-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.